Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.
about
Clinical applications of PD-L1 bioassays for cancer immunotherapy.Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy(89)Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.Current Development Status of MEK Inhibitors.Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization.A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.Protein kinase inhibitors for acute leukemia.Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma.Immuno-Oncology: Emerging Targets and Combination TherapiesDurvalumab in NSCLC: latest evidence and clinical potentialRole of noninvasive molecular imaging in determining responseEmerging therapies in advanced hepatocellular carcinomaTargeting the IDO1 pathway in cancer: from bench to bedsideClinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
P2860
Q33702815-54D2C3E8-46B7-4CB3-8228-039CAB9F92E1Q33814411-F31F3757-D5C8-4442-9D71-9E9FB1F3792FQ33876861-FDB65AFF-B528-4CA6-9BFC-2F138B477D39Q38598893-A56B26BB-92FE-4B12-8ED1-D8BFFCFF7CCDQ38617885-F4BBE076-34ED-4F69-B948-F7F0171D077EQ38642853-9022E7D8-9C6C-410B-A271-E52C2760E2ADQ46299389-022952E9-EF6D-4EFE-82D1-2B88B72EA23AQ47117702-1922A5AE-600B-4F74-8F36-273125F3B557Q47157402-DF34CA80-4E79-4ABF-9C91-E79042B6724AQ47375181-04B75B48-E12C-49EF-9192-7F085DB7271AQ47735535-E23DFA90-D943-4520-94D5-3F7DFAD9343EQ48107208-5E2629A7-A1EF-44A7-9987-EBB327CBE034Q48154177-B2C20200-6EF2-477E-8FCC-DC46AA9E8172Q49307383-ABB17405-C018-46BB-A80B-6B0371E01780Q49545290-0169728C-2854-4E38-9038-29B1F0B4B660Q49873905-D2C0EF26-7654-4112-9163-986C4E53AD6EQ52733768-582CA06B-0571-4BCE-B4E5-D14205A324D3Q56889817-625BF4CB-808C-4B38-A21D-709E712452B0Q57816055-8BF10CDE-E42E-4F05-AE42-5E4D619DC311Q58119177-5D648239-1191-4FCA-BAAE-EC1A6B6E11FAQ58802297-A549DF71-126B-4C30-B6F9-756881E0097AQ58803138-3B99FEEF-12B6-4805-91A9-7B42A00F3B7EQ59126078-4C7425A8-BCBD-457C-9880-32898A2AABD7
P2860
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Utility of PD-L1 immunohistoch ...... PD-1/PD-L1 inhibitor response.
@en
Utility of PD-L1 immunohistoch ...... PD-1/PD-L1 inhibitor response.
@nl
type
label
Utility of PD-L1 immunohistoch ...... PD-1/PD-L1 inhibitor response.
@en
Utility of PD-L1 immunohistoch ...... PD-1/PD-L1 inhibitor response.
@nl
prefLabel
Utility of PD-L1 immunohistoch ...... PD-1/PD-L1 inhibitor response.
@en
Utility of PD-L1 immunohistoch ...... PD-1/PD-L1 inhibitor response.
@nl
P2860
P1433
P1476
Utility of PD-L1 immunohistoch ...... PD-1/PD-L1 inhibitor response.
@en
P2093
Eddy C Hsueh
Laurence P Diggs
P2860
P2888
P356
10.1186/S40364-017-0093-8
P577
2017-03-15T00:00:00Z
P6179
1084252916